Home > Healthcare > Pharmaceuticals > Drug Delivery > oral transmucosal drugs market
Get a free sample of Oral Transmucosal Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Oral Transmucosal Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The oral transmucosal drugs industry is fragmented in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced product based on different technologies is among a key market strategy.
Some of the eminent market participants operating in the oral transmucosal drugs industry include:
North America market accounted for USD 13.5 billion in 2023 and is poised to grow at a notable rate from 2024-2032 owing to the increasing prevalence of diabetes in North America.
Some of the leading companies engaged in the industry are Aquestive Therapeutics, Inc, C.L.Pharm Co., Ltd., Cure Pharmaceutical., IntelGenx Technologies Corp, Jazz Pharmaceuticals, plc., NAL Pharma, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Limited., and ZIM Laboratories Limited.
Oral transmucosal drugs industry share from the tablets segment is anticipated to generate USD 30.1 billion by 2032 owing to the convenience and ease of administration offered by tablets contributing significantly to improved patient compliance.
Market Size for oral transmucosal drugs was worth around USD 34.3 billion in 2023 and is set to record around 6.7% CAGR from 2024-2032 driven by the increasing prevalence of chronic diseases coupled with the rising demand for oral transmucosal drugs.